Xeljanz approved for rheumatoid arthritis

(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.

RA is an autoimmune disease in which the immune system mistakenly attacks the body. In the case of RA, this leads to swelling of the joints and nearby tissues. About 1.5 million Americans have RA, the FDA said in a news release.

A twice-daily pill, Xeljanz is designed to block molecules involved in , the FDA said.

The drug was evaluated in seven clinical studies of adults with moderate-to-severe RA. The drug carries a "black box" label warning of an increased risk of infection triggered by a suppressed immune system, and tuberculosis and certain cancers.

Other serious side effects could include increased cholesterol levels and liver enzyme problems, the FDA said. More common adverse reactions were upper , headaches, diarrhea and nasal inflammation.

Xeljanz is marketed by New York-based .

More information: The U.S. National Library of Medicine has more about rheumatoid arthritis.

add to favorites email to friend print save as pdf

Related Stories

FDA panel urges approval for Pfizer arthritis drug

May 09, 2012

An advisory committee to the US Food and Drug Administration on Wednesday urged US regulators to approve a new treatment for rheumatoid arthritis made by the pharmaceutical giant Pfizer.

Pfizer says patient died in oral RA drug study

Apr 22, 2011

(AP) -- Pfizer Inc. confirmed that one patient who was taking its drug candidate tofacitinib, a pill designed to treat rheumatoid arthritis, died during a recent clinical trial and said the death was connected to the drug.

Study shows efficacy of new rheumatoid arthritis drug

Aug 09, 2012

(Medical Xpress) -- A new study involving researchers from Karolinska Institutet demonstrates the efficacy of Tofacitinib, a new drug for rheumatoid arthritis. According to the study, which is published in The New England ...

New biologic drug is effective against rheumatoid arthritis

Oct 06, 2009

Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review. The review examines recent trials to assess ...

Recommended for you

Low back pain? Don't blame the weather

Jul 10, 2014

Australian researchers reveal that sudden, acute episodes of low back pain are not linked to weather conditions such as temperature, humidity, air pressure, wind direction and precipitation. Findings published ...

One-third of knee replacements classified as inappropriate

Jun 30, 2014

New research reports that more than one third of total knee replacements in the U.S. were classified as "inappropriate" using a patient classification system developed and validated in Spain. The study, published in Arthritis & ...

User comments